A ‘mix and match’ approach to SARS-CoV-2 vaccination

Neutralizing Activity of BNT162b2-Elicited Serum

(2021) Yang Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots

(2021) Jacqui Wise   BMJ-British Medical Journal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

(2021) Shabir A. Madhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

(2021) Alexandra J. Spencer et al.   Nature Communications

Cellular and humoral response after MRNA‐1273 SARS‐CoV‐2 vaccine in kidney transplant recipients

(2021) David Cucchiari et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Seroconversion rates following COVID-19 vaccination among patients with cancer

(2021) Astha Thakkar et al.   CANCER CELL

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

(2021) Alberto M Borobia et al.   LANCET

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

(2021) Tina Schmidt et al.   NATURE MEDICINE

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

(2021) Joana Barros-Martins et al.   NATURE MEDICINE

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Feng-Cai Zhu et al.   LANCET

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

(2020) Denis Y Logunov et al.   LANCET

Prime-boost vaccine strategy against viral infections: Mechanisms and benefits

(2016) Kimia Kardani et al.   VACCINE